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ABSTRACT: Introduction: There is no therapeutic approach
that provides precise and rapidly reversible inhibition of motor
nerve and muscle activity for treatment of spastic hypertonia.
Methods: We used optogenetics to demonstrate precise and
rapidly reversible light-mediated inhibition of motor nerve and
muscle activity in vivo in transgenic Thy1::eNpHR2.0 mice.
Results: We found optical inhibition of motor nerve and muscle
activity to be effective at all muscle force amplitudes and deter-
mined that muscle activity can be modulated by changing light
pulse duration and light power density. Conclusions: This
demonstration of optical inhibition of motor nerves is an impor-
tant advancement toward novel optogenetics-based therapies
for spastic hypertonia.
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The upper motor neuron syndrome includes a
constellation of symptoms caused by lesions affect-
ing upper motor neuron pathways.1 These lesions,
which occur with cerebral palsy, stroke, and other
cerebrospinal injuries, frequently give rise to abnor-
mal activity in lower motor neurons and involuntary
muscle contractions through mechanisms that
remain unclear.1–4 Spastic hypertonia, a major fea-
ture of the upper motor neuron syndrome, is char-
acterized by exaggerated muscle activity in response
to muscle stretch. Individuals with spastic hyperto-
nia may be unable to perform voluntary move-
ments, such as walking, and experience significant
disability and reduced quality of life.3
Current approaches to inhibit motor nerve and
muscle activity for treatment of spastic hypertonia
have important limitations.2,3 Oral medications
such as dantrolene and tizanidine have poor
specificity and side effects, including sedation,
weakness, and withdrawal.3 Selective dorsal rhizot-
omy2 reduces spasticity through irreversible dam-
age of the nerve. Intramuscular injection of botuli-
num toxin diminishes spasticity by blocking release
of acetylcholine at the neuromuscular junction for
a period of several months, but its use is limited by
drug tolerance and muscle weakness.3 To date, no
clinical treatment provides precise and rapidly
reversible inhibition of motor nerve and muscle ac-
tivity to treat spastic hypertonia. Thus, a novel
means for precise, reversible inhibition is a long-
sought goal of neuroscience, bioengineering, and
clinical research.
Optogenetics employs light-sensitive proteins
encoded by microbial opsin genes to facilitate opti-
cal excitation or inhibition of metazoan neurons.5
This method capitalizes on the precision of gene
targeting of opsins to specific cell types and on the
speed of optical interrogation. Two opsins,
channelrhodopsin-2 (ChR2) and halorhodopsin
(NpHR), have been the most widely used tools for
optical deconstruction of neural circuits. When
illuminated with blue light, ChR2 allows sodium
ion influx into neurons causing membrane depola-
rization and excitation of action potentials.6 In
contrast, NpHR, when illuminated with yellow
light, pumps chloride ions into neurons, hyperpo-
larizing the membrane and inhibiting action
potentials.7 Optical excitation and inhibition have
been demonstrated in mammalian brain slices and
in brains of living mice.5 In the peripheral nervous
system, ChR2-mediated optical excitation of motor
nerve axons in the mouse sciatic nerve was used to
achieve orderly recruitment of motor units of
lower limb muscles.8 In addition, cardiomyocytes
in the mouse9 and rat10 and skeletal myocytes in
the developing chick embryo11 have been excited
with ChR2 and blue light. There have been no
reports of optical inhibition of motor nerve and
muscle activity in the peripheral nervous system.
The goal of this work was to determine whether
NpHR could be used in the peripheral nervous sys-
tem to inhibit motor nerve and muscle activity
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with light. We first sought to determine whether
enhanced NpHR (eNpHR2.0) is expressed in
axons of the sciatic nerve of Thy1::eNpHR2.0 mice.
We next sought to demonstrate optical inhibition
of muscle force and electromyographic activity and
measure the time precision of inhibition. We
examined inhibition over the range of electrically
stimulated muscle force and characterized the de-
pendence of inhibition on light power density.
METHODS
Histology and Expression Analysis. All animal pro-
cedures were approved by the institutional animal
care and use committee at Stanford University, in
accordance with the “Guide for the Care and Use
of Laboratory Animals” from the National Insti-
tutes of Health. Healthy adult male and female
Thy1::eNpHR2.0 and wild-type C57BL/6 mice, ages
8–14 weeks (average mass 26 g), were studied.
Thy1::eNpHR2.0 (line 2) mice were obtained from
Jackson Laboratories (Bar Harbor, Maine).
eNpHR2.0 is a modified version of NpHR that has
improved membrane localization and expression
along neuronal processes.12,13 The latter feature is
especially relevant for controlling motor nerves,
which have axons that span great distances from
cell somata in the spinal cord to muscles in the
periphery.
We performed histology and expression analysis
of the sciatic nerve to determine whether trans-
genic Thy1::eNpHR2.0 mice express eNpHR2.0
fused to enhanced yellow fluorescent protein
(EYFP) in the peripheral nervous system. We per-
fused animals with 4% paraformaldehyde and pre-
pared transverse 20-lm-thick nerve cryosections.
For expression analysis, nerves from transgenic
and control mice were processed on the same
slide. Histology was performed against laminin, a
basement membrane marker, as this protein is
highly expressed in the peripheral nervous system
and serves as a counterstain for axons. We labeled
sections with a primary antibody against laminin
(1:200; AL-4; Abcam, Cambridge, Massachusetts)
and a secondary antibody, Cy3-conjugated donkey
anti-rat (1:1000; Jackson Laboratories), using
standard histological protocols. Scans in the
EYFP channel were taken at 403 magnification
and 23 zoom at a low gain (600 PMT) and high
offset (1%) such that no fibers were saturated.
Representative raw images are shown in Figure S1
(refer to Supplementary Material available online).
eNpHR2.0 expression was sufficiently high so that
all axons in nerves from transgenic mice were
brighter than the background levels observed in
axons from wild-type mice. ImageJ software was
used to quantify mean fluorescence intensity and
diameter of individual fibers.14
In Vivo Measurements. We performed a series of
experiments to determine whether electrically
stimulated motor nerve and muscle activity could
be inhibited by illumination of the sciatic nerve in
anesthetized Thy1::eNpHR2.0 and wild-type mice.
Mice were anesthetized with isoflurane (1–3%) and
kept warm on an electrical heating pad (37C). The
hindlimb was shaved, and the sciatic nerve was
exposed. The triceps surae muscle group of the
lower limb was exposed, and the Achilles tendon was
isolated. The calcaneus was cut, and a small bone pi-
ece at the tendon was attached through a light-
weight, rigid hook to a force transducer (0.3-mN re-
solution; 300C-LR; Aurora Scientific, Aurora,
Ontario). Electromyography (EMG) electrodes
made from stainless steel, tetrafluoroethylene-coated
wires (50 lm; 790700; A-M Systems, Carlsborg, Wash-
ington) were inserted into the medial gastrocnemius
muscle belly and muscle–tendon junction with a
ground electrode at the forelimb wrist.
To initiate motor nerve activity we placed a cus-
tom-built stimulation cuff around the sciatic nerve
and applied electrical stimulation (Figs. 1 and S2).
The sciatic nerve includes motor and sensory
axons; however, only motor activity was investi-
gated here. Electrically stimulated motor axons
propagate action potentials to the lower limb
muscles to cause contractile and electrical muscle
activity. Contractile activity was recorded by the
force transducer, and electrical activity was
recorded by the EMG electrodes. To achieve
FIGURE 1. Schematic of experimental measurements. Motor
axons of the sciatic nerve were stimulated electrically with a
stimulation cuff placed around the proximal sciatic nerve of an
anesthetized Thy1::eNpHR2.0 mouse. The distal sciatic nerve
was illuminated with green laser light (561 nm). Fine-wire EMG
electrodes recorded electrical activity of the medial gastrocne-
mius. A force transducer attached at the Achilles tendon
recorded the contractile force of the lower limb muscles. [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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optical inhibition, we illuminated axons in the
nerve 1–3 mm distal to the electrical stimulation
cuff with green laser light.
Electrical Stimulation. Motor nerves were electri-
cally stimulated (S48 Stimulator; Grass Technolo-
gies, West Warwick, Rhode Island) through the
stimulation cuff. Supramaximal stimulation was
determined for each mouse by incrementally
increasing voltage until twitch force amplitude pla-
teaued. Stimulation voltage was alternately
increased and decreased for subsequent trials to
avoid possible temporal effects. Twitch stimulation
was 0.1-ms pulses at 1 HZ for 20 s. Tetanic stimula-
tion was 0.1-ms pulses at 100 HZ for 3 s at approxi-
mately 50% of supramaximal twitch force. Rest
periods were 20 s and 5 min between trials of
twitch and tetanus, respectively.
Illumination. Illumination was from a diode-
pumped solid-state yellow-green laser (561 nm;
CrystaLaser, Reno, Nevada) via a multimode opti-
cal fiber (400-lm diameter, 0.37 numerical aper-
ture; Thorlabs, Newton, New Jersey). The 561-nm
wavelength is within 70% of the eNpHR2.0 activa-
tion peak of 589 nm.15 Light power density was cal-
culated as the power at the fiber tip measured with
a power meter (PM100; Thorlabs) divided by the
light spot area of 1.0 mm2 illuminating the nerve
(diameter of approximately 1.1 mm). The interno-
dal length of C57BL/6 mouse sciatic nerve is
approximately 0.63 mm.16 Therefore, we expect
that this light spot illuminated, on average, 1 or 2
nodes of Ranvier per axon. The angle of light
incidence at the nerve surface was insufficient to
cause total internal reflection, assuming the nerve
refractive index is similar to that of brain.17 We
therefore expected that light would propagate
transversely through the nerve with minimal longi-
tudinal spreading. Average temperature increase at
the nerve (1.4C) during a 4-s pulse with 6.0 mW/
mm2 measured with a thermocouple (Omega,
Stamford, Connecticut) was below the average tem-
perature increase (2.1C) related to hyperthermia-
induced changes in rat hippocampal neurons after
10 min of heating (Table S1).18 Experiments with
Thy1::eNpHR2.0 and wild-type mice involved 3–6 h
of repeated electrical stimulation and illumination
(up to 200 trials per mouse). We observed no
localized nerve damage and no systematic change
in force or EMG during this time.
Data Recording and Analysis. Force and EMG data
were recorded at 10 kHZ (PCI-6251; National
Instruments, Austin, Texas) and analyzed using
MATLAB (The Mathworks, Natick, Massachusetts).
Passive force (muscle force with no activation)
was measured for each trial prior to electrical
stimulation of the nerve. Analyses were done on
the active (total 2 passive) force. Average peak
twitch force with light off (Fav_off) and light on
(Fav_on) were calculated for each trial of 20
twitches. Percent inhibition was (Fav_off 2 Fav_on) /
(Fav_off) * 100. Average tetanic force was calculated
with light off (1.1–1.9 s of trial duration, Fav_off)
and light on (2.1–2.9 s of trial duration, Fav_on).
Data that were collected in the 100-ms durations
after light onset and light offset were excluded
from calculations due to the rapid changes in
force amplitude. EMG was bandpass filtered (50–
300 HZ) and full-wave rectified, and percent inhibi-
tion was calculated using the same method as was
used for force. EMG amplitudes were normalized
to the twitch and tetanus maximum EMG ampli-
tudes observed in that mouse.
We quantified the time precision of inhibition
by measuring the time durations between light
onset and inhibition of tetanic force and between
light offset and reversal of inhibition. Inhibition was
defined to begin when force amplitude decreased
>2 standard deviations below the mean force prior
to illumination, and reversal was defined to occur
when force amplitude increased >2 standard devia-
tions above the mean force during illumination.
Statistics. Standard error of the mean (SEM) was
calculated from the variance of the mean calculated
for each mouse. P-values were calculated for unequal
sample size and unequal variance using a Welch t-
test (two-sided, a < 0.01) with degrees of freedom
calculated using the Welch–Satterthwaite equation.
RESULTS
Optical Inhibition of Motor Nerve and Muscle Activity
in Thy1::eNpHR2.0 Mice. Thy1::eNpHR2.0 mice
express eNpHR2.0-EYFP at high functional levels
throughout the brain,12 and we found that these
mice also express eNpHR2.0-EYFP in the periph-
eral nervous system. Confocal microscopy of EYFP
fluorescence revealed high levels of eNpHR2.0
expression within nearly all axons (>99%) of the
sciatic nerve (Fig. 2A). eNpHR2.0-EYFP appeared
localized to neuronal membranes (Fig. 2B). How-
ever, we observed variability in the level of expres-
sion across the neuronal population (Fig. 2B and
Fig. S1). No correlation was found between axon
diameter and level of expression (r2 5 0.11).
We observed robust and reversible inhibition of
electrically stimulated twitch and tetanic muscle
force and EMG by illuminating the sciatic nerve
with pulses of green light (Fig. 3A and B). Twitch
force and EMG amplitudes were inhibited during
4-s light pulses and returned to prior magnitudes
upon cessation of each light pulse. Representative
traces show >90% inhibition of twitch force and
EMG. Representative traces show 48% inhibition
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of tetanic force and 77% inhibition of EMG during
a 1-s light pulse. Thus, optical inhibition of motor
nerve activity is possible and causes substantial and
reversible inhibition of electrically stimulated mus-
cle activity.
We measured the times between onset and off-
set of the light pulse and inhibition of tetanic
force to quantify the time precision of optical inhi-
bition. Inhibition of tetanic force occurred 65 6
18 ms after light onset, and reversal of inhibition
occurred 38 1 5 ms (mean 6 SEM) after light off-
set (n 5 4 mice, 30 trials).
Inhibition over the Range of Electrically Stimulated
Force. We quantified inhibition of twitch force
and EMG amplitudes in Thy1::eNpHR2.0 mice and
wild-type mice (Fig. 4A and B) at force amplitudes
of approximately 50% of supramaximal force.
Illumination of the sciatic nerve with a light power
density of 6.0 mW/mm2 was sufficient to cause
inhibition in Thy1::eNpHR2.0 mice (mean 6 SEM:
83 6 3% and 84 6 4% for force and EMG, respec-
tively), indicating a significant difference from
wild-type mice (P 5 0.0000059 and 0.000087 for
force and EMG, respectively).
Without illumination, increasing stimulation
voltage increased twitch force amplitudes to gener-
ate a characteristic electrically stimulated motor
unit recruitment curve. During illumination, we
observed 81% inhibition of the plateau region of
the recruitment curve. The representative curves
demonstrate inhibition exceeding 74% at all
amplitudes of twitch force (Fig. 4C).
To further establish the relationship of inhibition
to force amplitude we determined percent inhibition
over the range of electrically stimulated twitch
forces in Thy1::eNpHR2.0 and wild-type mice
(Fig. 4D). We found effective inhibition at all
FIGURE 2. eNpHR2.0 expression in the sciatic nerve. (A) Confo-
cal image of a Thy1::eNpHR2.0 mouse sciatic nerve in cross-sec-
tion showing motor nerve axons expressing eNpHR2.0-EYFP
(green). An antibody against laminin (blue) labels glial cells sur-
rounding neurons. Scale bar: 100 lm. (B) eNpHR2.0-EYFP
appears localized to the membranes of motor nerve axons; stain-
ing as in (A). Scale bar: 20 lm.
FIGURE 3. Demonstration of optical inhibition. (A) Example force
and EMG data recorded during muscle twitches elicited by 20 s of
1-HZ supramaximal electrical stimulation (0.1-ms pulse duration,
red squares, n 5 1). EMG was full-wave rectified, filtered, and
normalized to the twitch and tetanus maximum amplitudes
recorded during the experiment. Average force and EMG ampli-
tudes were inhibited reversibly by 93% and 96%, respectively, dur-
ing 2 pulses of green light (4-s pulse duration, 14.6 mW/mm2,
green bars). (B) Example force and EMG data during muscle teta-
nus elicited by 3 s of 100-HZ 50% supramaximal electrical stimula-
tion (0.1-ms pulse duration, red line, n 5 1). Average force and
EMG amplitudes were inhibited by 48% and 77%, respectively,
during a pulse of green light (1-s pulse duration, 14.6 mW/mm2,
green bar).
FIGURE 4. Inhibition of minimum to maximum electrically
stimulated muscle activity with green light (6.0 mW/mm2). (A)
Percentage force inhibited by light in Thy1::eNpHR2.0 mice (n
5 5 mice, 21 trials) and wild-type mice (wt; n 5 3 mice, 20 tri-
als). Peak twitch force without illumination was 50% of supra-
maximal in all trials. Error bars show mean 6 SEM. (B)
Percentage EMG magnitude inhibited as in (A). (C) Represen-
tative motor unit recruitment curves of a Thy1::eNpHR2.0
mouse without and with illumination of the nerve. Each point
represents average peak twitch force during 1 trial (n 5 1
mouse). (D) Percentage force inhibited as in (A) over the range
from minimum to maximum electrically stimulated force in
Thy1::eNpHR2.0 mice (n 5 5 mice, 273 trials) and wild-type
mice (n 5 3 mice, 176 trials). Each point represents average
percent inhibition of 1 trial.
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amplitudes of twitch force with an average percent in-
hibition of 80 6 6%. Illumination did not cause inhi-
bition in wild-type mice (average percent inhibition5
1 6 4%). This relationship suggests that optical inhi-
bition may effectively reduce both chronic, low-level
muscle activity and brief bursts of high muscle activity.
Relationship between Optical Inhibition and Light
Power Density. We found that the degree of inhibi-
tion of twitch force was directly related to light power
density. As illumination was increased incrementally
up to 1.2 mW/mm2, twitch force inhibition
increased to 66 6 2% (Fig. 5A). The average slope in
this region was 57% per mW/mm2. As illumination
was further increased to 14.6 mW/mm2, inhibition
increased more modestly to 89 6 1%, with an aver-
age slope of 1% per mW/mm2. In the Supplemen-
tary Material, we provide a video demonstration of
increasing inhibition of twitch force with increasing
light power density (Video S1 and Fig. S3).
Tetanic forces were also modulated with
illumination. As illumination was increased incremen-
tally up to 1.2 mW/mm2, inhibition increased to 47 6
5% (Fig. 5B). The average slope in this region was
34% per mW/mm2. As illumination was further
increased to 14.6 mW/mm2, inhibition increased to 88
6 7%, with an average slope of 2% per mW/mm2.
DISCUSSION
In this study we have demonstrated NpHR-medi-
ated optical inhibition of motor nerve and muscle
activity in the peripheral nervous system. We found
that illumination of the sciatic nerve with 561 nm
laser light causes robust and reversible inhibition of
motor nerve activity and significantly reduces mus-
cle force and EMG in Thy1::eNpHR2.0 mice. The
data show that eNpHR2.0 is capable of intercepting
spikes in the axon, optical inhibition is effective at
all amplitudes of electrically stimulated twitch force,
and light power density modulates the degree of in-
hibition. The results demonstrate the potential of
NpHR as a powerful tool for inhibiting motor nerve
and muscle activity with light. Combined with opti-
cal excitation of muscle via illumination of ChR2-
expressing motor nerve axons,8 our method for op-
tical inhibition of muscle activity creates a powerful
toolbox for temporally precise control of peripheral
nerves and muscles with light.
Greater than 1 mW/mm2 is required to activate
eNpHR2.0, and light power density is reduced due to
scattering and absorption when light is transmitted
through rat and mouse cortex.13,19 Our results in
mouse sciatic nerve suggest that increasing light
power density at the nerve surface activates
eNpHR2.0 through greater depths of the nerve cross-
section. Percent inhibition increased most dramati-
cally as light power density became sufficient to acti-
vate eNpHR2.0 throughout the nerve cross-section.
Thus, we identified changing the light power density
as a means to modulate the degree of inhibition of
motor nerve and muscle activity. Further advance-
ment of optical inhibition in the peripheral nervous
system will require characterization of this relation-
ship for nerves with different diameters and compar-
ing various means to deliver light to the nerve.
Optogenetic approaches have facilitated the
deconstruction of numerous neural circuits in the
brain5 and may allow us to gain understanding of
FIGURE 5. Modulation of inhibition with light power density.
Peak force without illumination was 50% of supramaximal twitch
force in all trials. (A) Percent inhibition of twitch force in
Thy1::eNpHR2.0 mice (n 5 5 mice, 239 trials). Each point rep-
resents mean 6 SEM. Example force twitches show 26%, 61%,
and 88% inhibition with 0.4, 1.2, and 14.6 mW/mm2, respec-
tively. (B) Percent inhibition of tetanic force in Thy1::eNpHR2.0
mice (n 5 4 mice, 64 trials). Each point represents mean 6
SEM of 8 trials. Force decline due to fatigue was responsible
for nonzero (8%) inhibition at 0 mW/mm2. Example force trains
show 29%, 42%, and 85% inhibition at 1.2, 3.1, and 14.6 mW/
mm2, respectively. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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neural circuits in the peripheral nervous system
and the diseases associated with them. Peripheral
nerves can be excited with electrical stimulation
and inhibited with high-frequency alternating cur-
rent,20,21 but these electrical methods have limited
ability to control activity in selected nerve pools.
Although these results were obtained in transgenic
mice in which nearly all nerves were sensitive to
light, optogenetic methods enable activation and
inhibition of selected nerves by utilizing viral tar-
geting of opsins to these nerves.5 For example,
optogenetics enabled systematic targeting of differ-
ent elements of the Parkinson disease circuit.22
Selective optical stimulation in layer V of motor
cortex was found to ameliorate parkinsonian symp-
toms, elucidating underlying mechanisms of ther-
apy with deep brain stimulation. Future work that
enables cellular-level optogenetic control of spe-
cific motor nerves may allow dissection of the neu-
ral circuits involved in spasticity and provide a
novel means to elucidate the mechanisms of
spasticity.
Development of optogenetics-based therapies
will require selective, virus-mediated gene delivery
of NpHR or other opsins to non-transgenic motor
nerves in humans. Selective virus-mediated gene
delivery of fluorescent protein to distinct motor
neuron pools has been achieved in rodents and
nonhuman primates by retrograde transport of
adeno-associated virus (AAV) particles injected
intramuscularly.23,24 Gene delivery of NpHR has
shown high and well-tolerated neuron-specific
expression in nonhuman primates,25 and clinical
trials of gene delivery using a variety of AAV sero-
types in humans are underway.26–29 Future advan-
ces in gene-delivery techniques could achieve selec-
tive delivery of NpHR to nontransgenic motor
neurons in humans. Demonstration of long-term
safety and efficacy in combination with advances in
light delivery devices may enable clinical transla-
tion of robust, reversible, and selective optical inhi-
bition in humans to treat spastic hypertonia.
Although there are many challenges associ-
ated with the translation of this technique to
humans, the demonstration of optical inhibition
of motor nerve and muscle activity in transgenic
mice provides a first step toward novel optoge-
netics-based therapies for spastic hypertonia asso-
ciated with upper motor neuron syndrome and
hypertonicity associated with a wide range of
other diseases.
The authors thank M. Llewellyn, K. Thompson, and D.C. Lin for
technical assistance and K. McGill for valuable discussions.
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